Evidence map›Paper›PMID 39599737›Full record

Trial reportNutrients2024

Effect of Postbiotic

Malwina Naghibi, Adria Pont-Beltran, Araceli Lamelas, Laura Llobregat, Juan F Martinez-Blanch, Antonia Rojas, Beatriz Álvarez, Bricia López Plaza, Lucia Arcos Castellanos, Empar Chenoll and 2 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Trial
  2. Safety and Tolerance ofNutrients · 2025
    Trial
  3. Review
  4. Review
  5. Review
  6. Microorganisms · 2026
    Review
  7. Nutrients · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Emerging Nonthermal Technologies for the Production of Postbiotics.Comprehensive reviews in food science and food safety · 2025
    Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Malwina NaghibiMedical Department, ADM Health & Wellness, London SE1 7NT, UK.
Adria Pont-BeltranADM Research and Development Center-Valencia, ADM Health & Wellness, Parc Científic Universitat de València, 46980 València, Spain.ORCID 0009-0009-6540-9409
Araceli LamelasADM Research and Development Center-Valencia, ADM Health & Wellness, Parc Científic Universitat de València, 46980 València, Spain.ORCID 0000-0002-1939-5642
Laura LlobregatADM Research and Development Center-Valencia, ADM Health & Wellness, Parc Científic Universitat de València, 46980 València, Spain.
Juan F Martinez-BlanchADM Research and Development Center-Valencia, ADM Health & Wellness, Parc Científic Universitat de València, 46980 València, Spain.ORCID 0000-0002-8419-7909
Antonia RojasADM Research and Development Center-Valencia, ADM Health & Wellness, Parc Científic Universitat de València, 46980 València, Spain.ORCID 0000-0001-9833-7039
Beatriz ÁlvarezADM Research and Development Center-Valencia, ADM Health & Wellness, Parc Científic Universitat de València, 46980 València, Spain.
Bricia López PlazaFood, Nutrition and Health Platform, Hospital La Paz Institzonulute for Health Research (IdiPAZ), 28046 Madrid, Spain.ORCID 0000-0001-9310-1545
Lucia Arcos CastellanosFood, Nutrition and Health Platform, Hospital La Paz Institzonulute for Health Research (IdiPAZ), 28046 Madrid, Spain.ORCID 0000-0002-7977-0301
Empar ChenollADM Research and Development Center-Valencia, ADM Health & Wellness, Parc Científic Universitat de València, 46980 València, Spain.ORCID 0000-0002-6891-3573
Vineetha VijayakumarMedical Department, ADM Health & Wellness, London SE1 7NT, UK.ORCID 0000-0002-4295-7009
Richard DayMedical Department, ADM Health & Wellness, London SE1 7NT, UK.

Funding

Archer Daniels Midland (United States) NASpanish Ministry of Economy and Competitiveness, under the CDTI Project TOLERA IDI-20170876 TOLERA IDI-20170876
6 · The paper itself

Abstract

objectivesA randomised, double-blind, placebo-controlled pilot trial was conducted to assess the effect of heat-treated

methodsThis study monitored changes in the total Gastrointestinal Symptom Rating Scale for IBS score (GSRS-IBS), Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), IBS Quality of Life index (IBS-QoL), gut microbiome using 16S rRNA sequencing, and the Visceral Sensitivity Index, as well as a range of biochemical markers, anthropometric parameters, and adverse events.

resultsWhile minimal changes were observed in gastrointestinal (GI) symptoms, the HT-ES1 group showed a significant decrease in total and non-HDL cholesterol compared to the placebo. The intervention group also exhibited a significant increase in the abundance of the genera

conclusionsOverall, these findings suggest that HT-ES1 may promote gut health by increasing butyrate-producing bacteria in the gut, maintaining normal levels of faecal calprotectin and reducing serum cholesterol.

Indexed as

Bifidobacterium longumFecesGastrointestinal MicrobiomeProbioticsAdultDouble-Blind MethodFemaleHumansIrritable Bowel SyndromeLeukocyte L1 Antigen ComplexMaleMiddle AgedPilot ProjectsQuality of LifeYoung AdultLeukocyte L1 Antigen ComplexabundanceAnaerobutyricumAnaerostripesBlautiabutyratecalprotectinFaecalibacteriumgut healthhealthy populationinflammationmicrobiomePhocaeicolapostbioticsSCFAs

Identifiers

PMID39599737
PMCPMC11597252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.